JP2016094424A5 - - Google Patents

Download PDF

Info

Publication number
JP2016094424A5
JP2016094424A5 JP2015229465A JP2015229465A JP2016094424A5 JP 2016094424 A5 JP2016094424 A5 JP 2016094424A5 JP 2015229465 A JP2015229465 A JP 2015229465A JP 2015229465 A JP2015229465 A JP 2015229465A JP 2016094424 A5 JP2016094424 A5 JP 2016094424A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015229465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016094424A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016094424A publication Critical patent/JP2016094424A/ja
Publication of JP2016094424A5 publication Critical patent/JP2016094424A5/ja
Pending legal-status Critical Current

Links

JP2015229465A 2009-10-14 2015-11-25 EphA3に対する抗体 Pending JP2016094424A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25166809P 2009-10-14 2009-10-14
US61/251,668 2009-10-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012534368A Division JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体

Publications (2)

Publication Number Publication Date
JP2016094424A JP2016094424A (ja) 2016-05-26
JP2016094424A5 true JP2016094424A5 (enExample) 2016-10-06

Family

ID=43499991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体
JP2015229465A Pending JP2016094424A (ja) 2009-10-14 2015-11-25 EphA3に対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012534368A Pending JP2013508292A (ja) 2009-10-14 2010-10-14 EphA3に対する抗体

Country Status (11)

Country Link
US (2) US8664365B2 (enExample)
EP (1) EP2488554B1 (enExample)
JP (2) JP2013508292A (enExample)
CN (1) CN102666589B (enExample)
AU (1) AU2010313621C1 (enExample)
CA (1) CA2777068C (enExample)
DK (1) DK2488554T3 (enExample)
ES (1) ES2743558T3 (enExample)
PL (1) PL2488554T3 (enExample)
PT (1) PT2488554T (enExample)
WO (1) WO2011053465A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123819A2 (en) * 2010-04-01 2011-10-06 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of multiple myeloma
EP2582388A4 (en) * 2010-06-18 2014-04-16 Kalobios Pharmaceuticals Inc IDENTIFYING EPHA3 AS A MARKER FOR THE PRESENCE OF A SOLID TUMOR
EP2741774A4 (en) * 2011-08-12 2015-05-20 Kalobios Pharmaceuticals Inc METHOD FOR THE TREATMENT OF HEMATOLOGIC PROLIFERATIVE DISEASES BY TARGETING EPHA3 EXPRESSED ON ABERRANT VACCINATION SYSTEM IN THE BONE MARROW
CN105452296B (zh) 2013-08-01 2020-09-25 戊瑞治疗有限公司 无岩藻糖基化抗fgfr2iiib抗体
RU2745707C2 (ru) 2015-11-23 2021-03-30 Файв Прайм Терапьютикс, Инк. Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
EP3512883A1 (en) 2016-09-13 2019-07-24 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
LT3624837T (lt) 2017-05-16 2025-10-10 Anti-fgfr2 antikūnai derinyje su chemoterapijos agentais vėžio gydymui
US11795221B2 (en) 2018-02-28 2023-10-24 WuXi Biologics Ireland Limited Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof
IL291937A (en) * 2019-10-09 2022-06-01 Council Queensland Inst Medical Res Direct link to epha3 and its uses
AR120430A1 (es) * 2019-11-08 2022-02-16 Humanigen Inc Células car-t dirigidas a epha3 para el tratamiento de tumores
EP4232470A4 (en) * 2020-10-23 2025-01-15 Atreca, Inc. ANTIBODIES AGAINST CORONAVIRUS SARS-COV-2
JP7726496B2 (ja) * 2021-08-06 2025-08-20 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 新規な抗EphA2キメラ抗原受容体及びそれを発現する免疫細胞

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2111006C (en) 1991-06-21 2008-04-08 Andrew D. Boyd A novel receptor-type tyrosine kinase and use thereof
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
ATE440959T1 (de) 2000-06-28 2009-09-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP2339004B1 (en) 2002-03-19 2015-02-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
EP2343380B1 (en) 2004-11-16 2019-06-12 Humanigen, Inc. Immunoglobulin variable region cassette exchange
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008060092A1 (en) 2006-11-17 2008-05-22 Sang Yun Park Rotative force generator
CA2679986C (en) * 2007-03-08 2018-03-06 Martin Lackmann Epha3 antibodies for the treatment of solid tumors
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
WO2010102244A1 (en) 2009-03-06 2010-09-10 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3

Similar Documents

Publication Publication Date Title
JP2013508292A5 (enExample)
JP2023509196A5 (enExample)
JP2015520758A5 (enExample)
JP2016536361A5 (enExample)
JP2015534579A5 (enExample)
JP2022507487A5 (enExample)
EP4435009A3 (en) Claudin6 antibodies and methods of treating cancer
JP2018506277A5 (enExample)
JP2018534933A5 (enExample)
JP2017535257A5 (enExample)
JP2020536109A5 (enExample)
JP2017507652A5 (enExample)
JP2017529838A5 (enExample)
JP2011514150A5 (enExample)
JP2015503909A5 (enExample)
JP2014511179A5 (enExample)
JP2016188209A5 (enExample)
JP2009521496A5 (enExample)
JP2017515815A5 (enExample)
JP2014158469A5 (enExample)
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
RU2016100892A (ru) Антитела против tweakr и их применение
HRP20210778T1 (hr) Neutralizacija inhibitornih putova u limfocitima
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2010520290A5 (enExample)